Medicortex Developing New Biomarker Diagnostic Tools to Gauge Severity and Extent of Traumatic Brain Injuries and Strokes
Medicortex Finland Oy has established a new diagnostic division/arm to its core business with the goal of developing a biomarker diagnostic test that would reliably establish the severity and extent of brain injuries. The companion diagnostic will be coupled with Medicortex's signature pharmaceutical therapy that will limit the long-term effects of brain injuries, including the types of severe brain trauma that leads to strokes in patients.
View full press release